Introduction
Due to its reduced density, Helium/Oxygen (He/O 2 ) reduces the work of breathing, intrinsic PEEP and hypercapnia more than Air/O 2 during non-invasive ventilation (NIV) in COPD exacerbations [1, 2] . Two prospective, randomized multicenter trials were inconclusive in showing a benefit of He/O 2 NIV on outcome (intubation, mortality, length of stay (LOS) in ICU) but were potentially underpowered [3, 4] .
Objectives
To evaluate whether 72-hr continuous He/O 2 during both spontaneous breathing and NIV is superior to Air/ O 2 in reducing NIV failure (intubation or mortality during ICU stay) in severe hypercapnic COPD exacerbations. Secondary outcomes included physiological parameters, duration of ventilation, ICU and hospital LOS, 6-month recurrence and rehospitalization rates.
Methods
Prospective, randomized multicenter (16 centers in 6 countries) trial, comparing the two gas mixtures for a maximum of 72 hours. Hypothesis was that He/O 2 would reduce intubation rate from 25% to 15%, resulting in a total sample size of 670 patients. Spontaneous breathing and NIV were applied with specific devices for He/O 2 . Same ventilator was used in both arms.
Results
The trial was stopped prematurely for futility (low intubation rate reported by the adjudication committee). 445 patients were included (mean ± SD 68 ± 11 yrs; M:F 69:31%; BMI 26 ± 6 kg/m 2 ; SAPS 3 49 ± 8; Resp rate (RR) 29 ± 6/min -PaO 2 75 ± 36 mmHg; PaCO 2 69 ± 16 mmHg; pH 7.30 ± 0.06 -intention-to-treat data set), with no baseline difference between He/O 2 vs. Air/ O 2 . The primary outcome was negative ( Figure 1 ) and baseline pH was the only significant predictor of NIV failure. NIV failure occurred in the first 72 hours (while receiving the study treatment) in 58% of failures with He/O 2 and 84% with Air/O 2 (p = 0.97). RR (Figure 2) , pH, PaCO 2 and encephalopathy improved faster and with greater magnitude with He/O 2
Conclusions
NIV failure rate was not reduced by He/O 2 administered during NIV and spontaneous breathing for up to 72 hrs. Failure rate was low in both groups, reflecting the current efficacy of NIV in decompensated COPD. However, He/O 2 led to improved physiological response, thus confirming previous results, and a shorter duration of invasive ventilation and ICU stay in patients with NIV failure.
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